KindlyMD (NASDAQ:NAKA) CEO Purchases $175,770.00 in Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey purchased 31,500 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were purchased at an average price of $5.58 per share, for a total transaction of $175,770.00. Following the completion of the purchase, the chief executive officer directly owned 3,015,528 shares of the company’s stock, valued at $16,826,646.24. This represents a 1.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

KindlyMD Stock Up 11.8%

NASDAQ:NAKA opened at $6.26 on Friday. The stock’s fifty day moving average is $8.14 and its two-hundred day moving average is $13.02. KindlyMD, Inc. has a 52 week low of $4.50 and a 52 week high of $995.60. The stock has a market capitalization of $108.92 million, a price-to-earnings ratio of -0.14 and a beta of 17.12.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($15.20) EPS for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%.The firm had revenue of $2.68 million for the quarter. On average, sell-side analysts expect that KindlyMD, Inc. will post -16.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on NAKA shares. Weiss Ratings upgraded KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Maxim Group decreased their price target on KindlyMD from $60.00 to $30.00 and set a “buy” rating on the stock in a research note on Monday, April 6th. Wall Street Zen upgraded KindlyMD to a “sell” rating in a research note on Saturday, May 23rd. B. Riley Financial decreased their price target on KindlyMD from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Finally, TD Cowen assumed coverage on KindlyMD in a research note on Friday, April 10th. They issued a “buy” rating and a $40.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, KindlyMD presently has an average rating of “Hold” and a consensus target price of $30.00.

More KindlyMD News

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David Bailey bought 31,500 more shares at $5.58, adding to a recent series of insider purchases that may reassure investors about the company’s outlook. Article Title
• Positive Sentiment: Maxim Group reiterated a Buy rating on NAKA with a $30 price target, and its newer earnings forecasts imply a possible improvement in results over time. Article Title
• Neutral Sentiment: The analyst estimates still call for losses in the next several quarters, though they show a potential path toward profitability in fiscal 2027. Article Title
• Negative Sentiment: KindlyMD’s latest reported quarter showed a large EPS loss and very weak profitability, underscoring that the business remains highly speculative despite the recent stock strength. Article Title

Institutional Trading of KindlyMD

Several hedge funds have recently modified their holdings of the stock. Alyeska Investment Group L.P. acquired a new stake in shares of KindlyMD in the fourth quarter valued at $8,993,000. ParaFi Capital LP acquired a new stake in shares of KindlyMD in the third quarter valued at $443,055,000. Hunting Hill Global Capital LLC acquired a new stake in shares of KindlyMD in the fourth quarter valued at $4,672,000. RK Capital Management LLC FL acquired a new stake in shares of KindlyMD in the third quarter valued at $239,052,000. Finally, Yorkville Advisors Global LP acquired a new stake in shares of KindlyMD in the third quarter valued at $231,942,000.

KindlyMD Company Profile

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.